東京慈恵医科大学 総合医科研究センター遺伝子治療研究部
東京慈恵医科大学 総合医科研究センター遺伝子治療研究部 イメージ
TOP
研究者一覧
研究プロジェクト
業績
臨床研究
研究機器
研究機器
研究機器
リンク









研究部門

業 績

2016

•Shirai Y, Shiba H, Iwase R, Haruki K, Fujiwara Y, Furukawa K, Uwagawa T, Ohashi T, Yanaga K. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Cancer Lett. 2016 Jan 28;370(2):177-84. 

2015

•Higuchi T, Kobayashi M, Ogata J, Kaneshiro E, Shimada Y, Kobayashi H, Eto Y, Maeda S, Ohtake A, Ida H, Ohashi T. Identification of Cryptic Novel α-Galactosidase A Gene Mutations: Abnormal mRNA Splicing and Large Deletions. J Inherit Metab Dis. Reports. 2015 in press.

•Nakano S, Tsukimura T, Togawa T, Ohashi T, Kobayashi M, Takayama K, Kobayashi Y, Abiko H, Satou M, Nakahata T, Warnock DG, Sakuraba H, Shibasaki F. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy. PLoS One. 2015 Jun 17;10(6):e0128351.

•Shimada Y, Wakabayashi T, Akiyama K, Hoshina H, Higuchi T, Kobayashi H, Eto Y, Ida H,Ohashi T. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice. Mol Genet Metab. 2015 May 21. pii: S1096-7192(15)30008-1.

•Wakabayashi T, Shimada Y, Akiyama K, Higuchi T, Fukuda T, Kobayashi H, Eto Y, Ida H, Ohashi T.  Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.  Hum Gene Ther. 2015 Apr 20.

•Yokoi K, Akiyama K, Kaneshiro E, Higuchi T, Shimada Y, Kobayashi H, Akiyama M, Otsu M, Nakauchi H, Ohashi T, Ida H.  Effect of donor chimerism to reduce the level of glycosaminoglycans following bone marrow transplantation in a murine model of mucopolysaccharidosis type II.  J Inherit Metab Dis. 2015 Mar;38(2):333-40.

•Shimada Y, Nishimura E, Hoshina H, Kobayashi H, Higuchi T, Eto Y, Ida H, Ohashi T.  Proteasome Inhibitor Bortezomib Enhances the Activity of Multiple Mutant Forms of Lysosomal α-Glucosidase in Pompe Disease. JIMD Rep. 2015;18:33-9.

•Sato Y, Kobayashi H, Higuchi T, Shimada Y, Era T, Kimura S, Eto Y, Ida H, Ohashi T. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol Ther Methods Clin Dev. 2015 Jul 8;2:15023.

2014

•Sato Y, Kobayashi H, Sato S, Shimada Y, Fukuda T, Eto Y, Ohashi T, Ida H. Systemic accumulation of undigested lysosomal metabolites in an autopsy case of mucolipidosis type II; autophagic dysfunction in cardiomyocyte.  Mol Genet Metab. 2014 Jul;112(3):224-8.

•Higuchi T, Kawagoe S, Otsu M, Shimada Y, Kobayashi H, Hirayama R, Eto K, Ida H, Ohashi T, Nakauchi H, Eto Y. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs. Mol Genet Metab. 2014 May;112(1):44-8.

•Akiyama K, Shimada Y, Higuchi T, Ohtsu M, Nakauchi H, Kobayashi H, Fukuda T, Ida H, Eto Y, Crawford BE, Brown JR, Ohashi T. Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice. Mol Genet Metab. 2014 Feb;111(2):139-46.

 

2013

•Iwase R, Haruki K, Fujiwara Y, Furukawa K, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K.Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation. J Surg Res. 2013 Sep;184(1):605-12.

•Haruki K, Shiba H, Fujiwara Y, Furukawa K, Iwase R, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice. Surgery. 2013 Sep;154(3):468-78.

•Haruki K, Shiba H, Fujiwara Y, Furukawa K, Iwase R, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice. Dig Dis Sci. 2013 Jan;58(1):123-31.

•Sato T, Ikeda M, Yotsumoto S, Shimada Y, Higuchi T, Kobayashi H, Fukuda T, Ohashi T, Suda T, Ohteki T. Novel interferon-based pre-transplantation conditioning in the treatment of a congenital metabolic disorder. Blood. 2013 Apr 18;121(16):3267-73.

•Furukawa K, Uwagawa T, Haruki K, Fujiwara Y, Iida T, Shiba H, Misawa T, Ohashi T, Yanaga K. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Surg Today. 2013 Feb;43(2):171-7.

•Fujiwara Y, Shiba H, Iwase R, Haruki K, Furukawa K, Uwagawa T, Misawa T, Ohashi T, Yanaga K.  Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice. J Am Coll Surg. 2013 Feb;216(2):320-32.

 

2012

•Nishiyama Y, Shimada Y, Yokoi T, Kobayashi H, Higuchi T, Eto Y, Ida H, Ohashi T. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease. Mol Genet Metab. 2012 Nov;107(3):490-5.

• Ohashi T, Iizuka S, Shimada Y, Higuchi T, Eto Y, Ida H, Kobayashi H. Administration of Anti-CD3 Antibodies Modulates the Immune Response to an Infusion of α-glucosidase in Mice. Mol Ther. 2012 Oct;20(10):1924-31.

• Haruki K, Shiba H, Fujiwara Y, Furukawa K, Wakiyama S, Ogawa M, Ishida Y, Misawa T, Yanaga K. Perioperative change in peripheral blood monocyte count may predict prognosis in patients with colorectal liver metastasis after hepatic resection. J Surg Oncol. 2012;106(1):31-5.

• Higuchi T, Shimizu H, Fukuda T, Kawagoe S, Matsumoto J, Shimada Y, Kobayashi H, Ida H, Ohashi T, Morimoto H, Hirato T, Nishino K, Eto Y. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Mol Genet Metab. 2012;107(1-2):122-8.

2011

•Ohashi T, Iizuka S, Shimada Y, Eto Y, Ida H, Hachimura S, Kobayashi H. Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse. Mol Genet Metab. 2011;103(1):98-100.

•Yokoi T, Kobayashi H, Shimada Y, Eto Y, Ishige N, Kitagawa T, Otsu M, Nakauchi H, Ida H, Ohashi T. Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease.J Gene Med. 2011;13(5):262-8.

•Fujiwara Y, Furukawa K, Shimada Y, Iida T, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer. Pancreas. 2011;40(4):600-7.

•Furukawa K, Ohashi T, Haruki K, Fujiwara Y, Iida T, Shiba H, Uwagawa T, Kobayashi H, Yanaga K. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice. Cancer Lett. 2011;306(1):92-8.

•Fujiwara Y, Furukawa K, Haruki K, Shimada Y, Iida T, Shiba H, Uwagawa T, Ohashi T, Yanaga K. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. J Hepatobiliary Pancreat Sci. 2011;18(5):731-9.

•Matsumoto K, Yokoo T, Yokote S, Utsunomiya Y, Ohashi T, Hosoya T. Functional development of a transplanted embryonic kidney: effect of transplantation site. J Nephrol. 2011 Apr 13.pii: 4C3C9744-4467-4DC9-8E85-5BFCF7AC0BA7. doi: 10.5301/JN.2011.7426

•Kawagoe S, Higuchi T, Meng XL, Shimada Y, Shimizu H, Hirayama R, Fukuda T,Chang H, Nakahata T, Fukada SI, Ida H, Kobayashi H, Ohashi T, Eto Y. Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells. Mol Genet Metab. 2011;104(1-2):123-8.

•Shimada Y, Kobayashi H, Kawagoe S, Aoki K, Kaneshiro E, Shimizu H, Eto Y, Ida H, Ohashi T. Endoplasmic reticulum stress induces autophagy through activation of p38 MAPK in fibroblasts from Pompe disease patients carrying c.546 G> T mutation.
Mol Genet Metab. 2011;104(4):566-73.

•Shimada Y, Nishida H, Nishiyama Y, Kobayashi H, Higuchi T, Eto Y, Ida H, Ohashi T.Proteasome inhibitors improve the function of mutant lysosomal alpha-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.Biochem. Biophys. Res. Commun., 2011;415(2):274-8.

•Kobayashi H, Shimada Y, Ikegami M, Kawai T, Sakurai K, Urashima T, IjimaM,Fujiwara M, Kaneshiro E, Ohashi T, Eto Y, Ishigaki K, Osawa M, Kyosen SO, IdaH. Pathology of the first autopsy case diagnosed as mucolipidosis type III alpha/beta suggesting autophagic dysfunction.Mol Genet Metab.2011;102(2):170-5.

2010

•Kobayashi H, Shimada Y, Ikegami M, Kawai T, Sakurai K, Urashima T, Ijima M, Fujiwara M, Kaneshiro E, Ohashi T, Eto Y, Ishigaki K, Osawa M, Kyosen SO, Ida H. Pathology of the first autopsy case diagnosed as mucolipidosis type III alpha/beta suggesting autophagic dysfunction..  Mol Genet Metab. 2010 May;100(1):14-9.

•Furukawa K, Iida T, Shiba H, Fujiwara Y, Uwagawa T, Shimada Y, Misawa T, Oha shi T, Yanaga K. Anti-tumor effect by inhixbition of NF-κB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncol Rep.2010;24: 843-850.

•Kobayashi H, Shimada Y, Ikegami M, Kawai T, Sakurai k, Urashima T, Iijima M, Fujiwara M, Kaneshiro E, Ohashi T, Eto Y, Ishigaki K, Osawa M, Kyosen OS, Ida H. Prognostic factors for the Late Onset Pompe Disease with Enzyme Replacement Therapy: From Our Experience of 4 cases including an autopsy case. Mol Genet Metab. 2010;100(1):14-9.

• Tajima A, Ohashi T, Hamano S, Higurashi N, Ida H. Gaucher Disease Patient With Myoclonus Epilepsy and a Novel Mutation. Pediatr Neurol 2010;42:65-68.

• Fujiwara Y, Shiba H, Furukawa K, Iida T, Haruki K, Gocho T, Wakiyama S, Hirohara S, Ishida Y, Misawa T, Ohashi T, Yanaga K. Glasgow prognostic score is related to blood transfusion requirements and post-operative complications in hepatic resection for hepatocellular carcinoma. Anticancer Res. 2010 Dec;30(12):5129-36.

•Fujiwara Y, Shiba H, Furukawa K, Iida T, Sakamoto T, Gocho T, Wakiyama S, Hirohara S, Ishida Y, Misawa T, Ohashi T, Yanaga K. Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2010 Nov;17(6):892-7.


▲